Helmholtz Munich’s Post

#PaperoftheDay: "A novel t (5; 17) (q35; q21) associated with t (8; 21) (q22; q22) in a patient with acute myeloid leukemia: case report and review of literature" DOI ⬇️ https://lnkd.in/er9uhebs #aml #leukemia #cancer #research #openaccess #peerreviewed #publishing

Today we are excited to announce our collaboration with NMDP BioTherapies to advance our TCR T-cell therapy into human trials. NMDP BioTherapies will provide healthy donor materials for our upcoming Phase 1/2a trial (TCX-101) of our first-in-human product (BSB-1001). The Phase 1/2a trial will evaluate BSB-1001 in combination with allogeneic stem cell transplant in patients with high-risk leukemias, including relapsed or refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and myeloid dysplastic syndrome (MDS). Learn more here: https://lnkd.in/g4C5kxdy

Post-allo-HSCT outcomes for #AML show: ▪️3-year relapse rate changed from 37%-31% and then to 30% from 2000-2021 ▪️3 year leukemia-free survival increased from 32%, 38% and, 44% ▪️OS increased from 37%, 42%, and 49% https://lnkd.in/ekejs_5d #leusm #cancer #oncology

#PaperSpotlight: On March 14, 2024, researchers Benigno C. Valdez, Bin Yuan, David Murray, Jeremy L. Ramdial, Uday Popat, Yago Nieto, and Borje S. Andersson from The University of Texas MD Anderson Cancer Center and the University of Alberta published a new research paper in Oncotarget, entitled, “ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells.” “[...] the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.” #PressRelease: https://lnkd.in/ezeVgz_M #cancerresearch #aml #leukemia #cells #oncology #medicine #openaccess #openscience #peerreview #journal #publication #publishing #meded

2023 FDA Approvals in Leukemia, Lymphoma, Multiple Myeloma and Other Blood Cancers 2023 saw 17 novel approvals in leukemia, lymphoma, multiple myeloma and other blood cancers. ✅ Three approvals in leukemia (one each in #AML, #CML and T-cell lymphoblastic leukemia) ✅ Six approvals in #lymphoma (two approvals in #CLL; three approvals in #DLBCL; and 1 approval in #MCL) ✅ Four approvals in #multiplemyeloma Looking forward to a fruitful 2024. #Leukemia #Lymphoma #MultipleMyeloma #oncology #patientcentricity #innovation

📄 [Press release] – MaaT Pharma Announces First DSMB Positive Review of Ongoing Phase 2 Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT 🩸 Key highlights: ✅ DSMB recommends proceeding as planned without modifications ✅ MaaT033 has shown to have an acceptable safety profile and was well tolerated in patients treated for blood cancers and receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). 🦠Phase 2b trial PHOEBUS, the largest one to date for a microbiome therapy in oncology, is an international, multi-center, randomized, double-blind, testing MaaT033, an oral freeze-dried formulation against placebo. https://lnkd.in/emffi3dR #Microbiome #BloodCancer #Cancer #DSMB #Safety

Visit www.Oncotarget.org to read blog synopses of new and trending research papers published by Oncotarget. #openaccess #peerreviewed #oncology #cancer #researchpapers #science #medicine #medEd #OA

On July 30, 2024, the FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), in combination with Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma was needed. This study has shown that the addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. #Cancer #Oncology #multiplemyeloma #ASCT #Darzalex #DarzalexFaspro #daratumumab #Moffitt #MoffittCancerCenter Moffitt Cancer Center

3 Reasons why you should attend the Lymphoma, Leukemia & Myeloma Congress this October: 1. Enhancing relationships with your colleagues and meeting new peers that share the same interest 2. Gain direct access to industry experts to advance your connections and knowledge 3. Learning about new advancements and best practices in hematologic malignancies to best treat your patients. Why wait to register? Rates increase after August 2: https://lnkd.in/e2i8XbKr #llmcongress2024 #lymphoma #leukemia #myeloma #bloodcancers #oncology #education #networking #patientcare

#4 Cancer treatment The landscape of cancer treatment is continuously evolving, driven by scientific innovation and clinical research. Key therapeutic modalities include surgical oncology, radiotherapy, chemotherapy, hyperthermia, immunotherapy (such as checkpoint inhibitors and CAR-T cells), targeted therapy, hormonal therapy, and hematopoietic stem cell transplantation.  Recent advancements like precision oncology tailor treatments based on comprehensive genomic profiling, allows optimizing efficacy and minimizing side effects. Moreover, CRISPR-Cas9 gene editing and nanomedicine are revolutionizing cancer therapy, while ongoing trials are assessing vaccines designed to elicit robust immune responses against tumor-specific antigens, with applications in both prophylactic and therapeutic settings. These advancements point to a future of more precise and personalized cancer treatment, driven by innovations in research and clinical practice. #EWAC2024